AstraZeneca Partners With Huma Therapeutics To Launch A Digital Health Initiative

AstraZeneca partnered with Huma Therapeutics to launch an initiative to scale innovation for digital health. Huma and AstraZeneca intend to launch software as a medical device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate adoption of SaMDs to facilitate decentralized clinical trials. Financial terms have not been disclosed.

As part of the deal, Huma will also acquire AstraZeneca’s disease management platform AMAZE, which was developed for people with asthma and heart failure. The platform shares critical data with clinical professionals on consumer health progress and enables in-app messaging between health care professionals . . .